Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06920043 · ClinicalTrials.gov registry record · Phase 2
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
A Phase 2 study of Metabolic Dysfunction-associated Steatohepatitis, sponsored by Boston Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 20
- Study locations
NCT06920043 is a Phase 2 study of Metabolic Dysfunction-associated Steatohepatitis that is actively recruiting participants, run by Boston Pharmaceuticals. The registered enrollment target is 42 participants, below the 413-participant average among 5 other Metabolic Dysfunction-associated Steatohepatitis trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT06920043, a Phase 2 study of Metabolic Dysfunction-associated Steatohepatitis, is actively recruiting participants, sponsored by Boston Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Efimosfermin
Study Locations (20)
California
- Fresno Clinical Research Center - Fresno
- OM Research LLC - Lancaster
- Knowledge Research Center - Orange
- California Liver Research Institute - Pasadena
- Inland Empire Liver Foundation - Rialto
- Santa Maria Gastroenterology Center - Santa Maria
Arizona
- Arizona Liver Health - Chandler - Chandler
- Arizona Liver Health - Peoria - Peoria
- The Institute for Liver Health II LLC dba Arizona Liver Health - Tucson - Tucson
Florida
- ClinCloud Research - Maitland - Maitland
- ClinCloud Research - Viera - Melbourne
- Advanced Clinical Research of Miami - Miami
Georgia
- Centricity Research - Columbus - Columbus
- Gastrointestinal Specialists of Georgia PC - Marietta
North Carolina
- Coastal Research Institute, LLC - Fayetteville
- M3 Wake Research, Inc - Raleigh
Maryland
- Mercy Medical Center - Baltimore, Maryland - Baltimore
Mississippi
- Gastrointestinal Associates and Endoscopy Center, PA - Flowood - Flowood
Missouri
- Kansas City Research Institute - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2025-04-09 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06920043
The ClinicalTrials.gov registry entry for NCT06920043 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 413-participant average among 5 other Metabolic Dysfunction-associated Steatohepatitis trials with a reported enrollment target (90% lower). The listed sponsor is Boston Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metabolic Dysfunction-associated Steatohepatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06920043 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT06920043 about?
NCT06920043 is a clinical study titled "A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH". The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.
What is the current status of trial NCT06920043?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2025-04-09. Estimated completion is 2027-12.
What conditions does trial NCT06920043 study?
This clinical trial studies the following conditions: Metabolic Dysfunction-associated Steatohepatitis.
What interventions are being tested in trial NCT06920043?
The interventions under investigation include: Placebo (DRUG), Efimosfermin (DRUG).
Who is sponsoring clinical trial NCT06920043?
This trial is sponsored by Boston Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06920043 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metabolic Dysfunction-associated Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
RECRUITING · Phase 2
-
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
ACTIVE NOT RECRUITING · Phase 2
-
ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)
COMPLETED · Phase 2
-
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
RECRUITING · NA
-
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.